Back to News
Market Impact: 0.38
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit
Source: GlobeNewswire
Healthcare & BiotechLegal & LitigationRegulation & LegislationCompany Fundamentals
Replimune shareholders who purchased REPL between October 20, 2025 and April 10, 2026 may retain federal securities-law claims after the FDA rejected the biologics license application for RP1. The rejection allegedly wiped out more than 80% of the stock's value during the class period, creating significant litigation and regulatory risk for the biotech company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.78
Ticker Sentiment
REPL-0.95
More News
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Paramount will need to release way more movies to make this merger work
- Sullivan: Wall Street admits it doesn't know where oil is headed. There's one stock they do agree on
- U.S. regulators rush to write crypto rulebook after Clarity Act stalls in Senate
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- We Want This Country to Win Tokenization: SEC's Selway